Dublin, Jan. 20, 2021 (GLOBE NEWSWIRE) -- The "Global Pulmonary Arterial Hypertension (2020-2025) by Drug Class, Route of Administration, Distribution Mode, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
The Global Pulmonary Arterial Hypertension Market is estimated to be USD 7.4 Bn in 2020 and is expected to reach USD 9.9 Bn by 2025, growing at a CAGR of 6%.
Some of the factors that impact the growth of the global pulmonary arterial hypertension market are the change in the lifestyles, rising geriatric population, and the increasing prevalence of pulmonary arterial hypertension (PAH). Several Government and private sector initiatives such as the rare disease act and the orphan drug act that create awareness and offer incentives such as tax waivers, credits, assistance & support are expected to contribute to the growth rate of the global pulmonary arterial hypertension market.
However, discontinuing of drug production by major players during clinical trials and stringent regulations by Government, lack of awareness about the presence of pulmonary arterial hypertension among patients, and high diagnosis and treatment cost are expected to hinder the market growth. Technology advancements such as biomarker and new gene therapy for the treatment and advanced oral drugs create an opportunity for the market.
Growing Burden of Pulmonary Arterial Hypertension
Government and Private Support for the Development of Orphan Drugs
Growing Geriatric Population
Patent Expiration of Key Molecules
Side Effects Associated with the Drugs
Lack of Awareness among People in Developing Countries
High Costs of Diagnosis and Treatment
Lack of Awareness
Expiry of Patents
Advance Oral Drugs for Pulmonary Arterial Hypertension
Technology Advancements such as Biomaker and New Gene Therapy for the Treatment
Based on Drug Class, the pulmonary arterial hypertension (PAH) market has been segmented into Soluble Guanylate Cyclase (SGC) stimulators, prostacyclin and prostacyclin analogs, phosphodiesterase 5 (PDE-5), and Endothelin Receptor Antagonists (ERA). ERA And Prostacyclin And Prostacyclin Analogs for treating PAH have the largest market share owing to the significant increase in the sales of this drug for the treatment of pulmonary arterial hypertension.
Based on Distribution Mode, Online Pharmacies is expected to grow at the highest CAGR during the forecast period. An increase in preferences for e-commerce platforms and also due to the benefits provided by the online pharmacies like discounts & home delivery are fueling the growth of the market.
Based on Route of Administration, the Oral Route is expected to have the largest share of the market. This is because of the wide range of benefits associated with oral drugs. The oral route is one of the simplest, most convenient, and safest routes.
North America is anticipated to have a large market share due to the developed healthcare infrastructure in the developed countries like U.S. that has access to advanced therapeutics for treating PAH. Increasing awareness about Pulmonary Arterial Hypertension, a growing diagnosis rate, and supportive government initiatives resulted in an increased demand for PAH diagnosis and treatment. Europe is followed by North America. The rising geriatric population, changes in lifestyle, and exposure to pollution is anticipated to contribute toward the increasing prevalence of PAH in Europe.
Some of the companies covered in this report are United Therapeutics Corporation, GlaxoSmithKline plc, Novartis International AG, AstraZeneca, Bayer Healthcare AG, Pfizer Inc., Gilead Sciences, Actelion Pharmaceuticals Ltd, Arena Pharmaceuticals, and Daiichi Sankyo Company Limited. and others.
The report includes Infogence Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.
Lions: Represents companies with a strong foothold in the market, with the highest market share, large investments in technologies, new products.
Bulls: Companies that are medium in size competing with their USPs, growing companies with proven market share.
Rabbits: Small companies but growing rapidly, constantly improving their offerings in the market.
Tortoise: Companies that are slow in growth, having a long legacy, and stable or negative in performance.
Why buy this report?
The report offers a comprehensive evaluation of the Global Pulmonary Arterial Hypertension Market.
The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
The report includes in-depth market analysis using Porter's 5 force model and the Ansoff Matrix. The impact of Covid-19 on the market is also featured in the report.
The report also contains a competitive analysis using the Competitive Quadrant, a Proprietary competitive positioning tool.
A complete analysis of the market including parent industry
Important market dynamics and trends
Historical, current, and projected size of the market based on value and volume
Market shares and strategies of key players
Recommendations to companies for strengthening their foothold in the market
Key Topics Covered:
1. Report Description
1.1 Study Objectives
1.2 Market Definition
1.4 Years Considered
1.6 Key Shareholders
2. Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.3 Market Size Estimation
2.4 Assumptions of the Study
2.5 Limitations of the Study
3. Executive Summary
4. Market Overview
4.2 Market Dynamics
5. Market Analysis
5.1 Porter's Five Forces Analysis
5.2 Impact of COVID-19
5.3 Ansoff Matrix Analysis
6. Global Pulmonary Arterial Hypertension Market, By Drug Class
6.2 Prostacyclin and Prostacyclin Analogs
6.3 Soluble Guanylate Cyclase (Sgc) Stimulators
6.4 Endothelin Receptor Antagonists (ERAs)
6.5 Phosphodiesterase 5 (Pde-5)
6.6 Calcium Channel Blockers
7. Global Pulmonary Arterial Hypertension Market, By Route of Administration
8. Global Pulmonary Arterial Hypertension Market, By Distribution Mode
8.2 Hospital Pharmacy
8.3 Online Pharmacy
8.4 Retail Pharmacy
9. Global Pulmonary Arterial Hypertension Market, By Geography
9.2 North America
9.3 South America
9.4.6 Rest of Europe
9.5.6 South Korea
9.5.9 Rest of APAC
9.6 Rest of the World
9.6.2 Saudi Arabia
9.6.3 South Africa
9.6.4 United Arab Emirates
9.6.5 Latin America
10. Competitive Landscape
10.1 Infogence Competitive Quadrant
10.2 Market Share Analysis
10.3 Competitive Scenario
10.3.1 Mergers & Acquisitions
10.3.2 Agreements, Collaborations, & Partnerships
10.3.3 New Product Launches & Enhancements
10.3.4 Investments & Fundings
11. Company Profiles
11.1 Gilead Sciences, Inc.
11.2 United Therapeutics Corporation
11.3 Novartis International AG
11.4 GlaxoSmithKline Plc. (GSK)
11.5 Pfizer, Inc.
11.6 Dong-A ST Co., Ltd.
11.7 Merck Sharp & Dohme Corp.
11.8 Bayer HealthCare AG
11.9 Arena Pharmaceuticals
11.10 Actelion Pharmaceuticals Ltd
11.11 Daiichi Sankyo Company, Limited
11.12 Gilead Sciences
11.13 Johnson & Johnson
11.15 Bristol-Myers Squibb Company
For more information about this report visit https://www.researchandmarkets.com/r/mqgah7
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900